Jeffrey Clarke, MD
Dr. Clarke is a medical oncologist within Duke Health and the Duke Cancer Institute in Durham, North Carolina. He specializes in treating patients with cancers of the chest, including malignant mesothelioma and lung cancer. He says that the most rewarding part of his work is developing long-term relationships with his patients and their families throughout their cancer journeys.[1]
Dr. Clarke says that with each patient interaction, it is his goal is to individualize the care he provides. He does that by focusing on their symptoms and choosing therapies that are appropriate for them based on his understanding of their goals and what’s most important for their lives.
Education and Career
Dr. Clarke attended medical school at the Indiana University School of Medicine and then completed his internship and residency in Internal Medicine at Duke University Medical Center, where he was named Chief Resident of Internal Medicine. He remained at Duke to complete a fellowship in Medical Oncology and has been a faculty member there ever since.[1]
Today he is an Associate Professor of Medicine with the Duke University School of Medicine and a member of the Duke Cancer Institute.
Research
Dr. Clarke is actively involved in research focused on non-small cell lung cancer and malignant mesothelioma. He is the principal investigator on a study titled “Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer and is also part of a Duke University team that is collaborating with researchers at Baylor College of Medicine on a clinical trial for patients with mesothelioma to determine whether the combination of chemotherapy with immunotherapy before surgery delivers better outcomes.[2]
Dr. Clarke has received 38 grants, the most recent of which include:
- Amgen 20190341 awarded by Amgen, Inc. 2023 – 2028
- GT103_HCRN_NSCLC awarded by Hoosier Cancer Research Network, Inc 2023 – 2027
- Amgen AMG 757 (SCLC) awarded by Amgen, Inc. 2022 – 2027
- A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients with Advanced Mesothelin-Expressing Cancer awarded by TCR2 Therapeutics Inc. 2023 – 2027
- An Open-Label, Multi-Center Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON) awarded by Achilles Therapeutics 2021 – 2026
- A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer awarded by Arcus Biosciences 2021 – 2026
- Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated Brain Metastases (HCRN-LUN19-247) awarded by Genentech, Inc. 2020 – 2025
- Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumors to enable the development of methods for the manufacturing of clonal neoantigen T cell products (cNeT). awarded by Achilles Therapeutics 2020 – 2025
- A Phase 1b Study Evaluating the Safety and Tolerability, and Efficacy of AMG510 in Combination with Everolimus awarded by Amgen, Inc. 2022 – 2025
He has participated in writing 56 academic articles and co-authored two book sections. He has also presented eight conference papers to meetings of medical professionals.
